

Review Article

The Golden Role of Natural Products in Obesity

Gehan F Abdel Raouf^{1,*}, Aya M Z Abd El Kareem²

¹Pharmacognosy Department, Pharmaceutical and Drug Research Industries Division, National Research Centre, Dokki, Giza 12622, Egypt.

²College of Biotechnology, Misr University for Science and Technology (MUST), Egypt.

ARTICLE INFO:

Received: 10 Nov 2020
Accepted: 18 Dec 2020
Published: 30 Dec 2020

Corresponding author *

Gehan Fawzy Abdel Raouf
Kandeel,
Researcher (Lecturer) at National
Research centre
Elbehoos Street, Dokki 12622,
Giza, Egypt.
E Mail:
ahmedkhaled_1@hotmail.com

ABSTRACT:

Objective: Obesity is considered a serious syndrome that can have a negative impact on the whole systems in the body which leads to many health problems, such as osteoarthritis, heart disease, diabetes, and certain cancers. Up to date reports revealed that there are more than 700 million obese people throughout the world. However, surgery and synthetic drugs may be a choice for the treatment of obesity; they showed unsatisfying results with serious adverse effects. So the best option for the management of obesity is a lifestyle modification together with using natural alternatives that showed the minimal side effects. Natural Products are rich of bioactive compounds that have been used as traditional medicine. Some active natural products were tested by clinical trials and they showed a powerful impact in the treatment of obesity.

Aim: This review is focused on the recent advances in the natural products as anti-obesity potential. A major focus is to highlight the mechanisms of action of natural products as anti-obesity agents, as well as the structure-activity studies, preclinical and clinical trials were also discussed.

Results: The current review revealed that natural products include diversity of phytoconstituents that play an important role in the treatment of obesity.

Keywords: Anti-obesity, bioactive compounds, natural products, Obesity.

1. INTRODUCTION

Obesity is a medical condition in which excess body fat accumulates as a result of imbalance between energy intake and energy expenditure [1]. It is a major public health problem that leads to many diseases, including type 2 diabetes mellitus, hypertension, dyslipidemia, coronary heart disease, some cancers, osteoarthritis, kidney disease, and sleep disorders [2]. Body mass index is used to identify excess weight and obesity based on epidemiologic research. Particularly in females, there is a relation between body mass index and lifestyle. Body mass index can be calculated by dividing the weight (kg.) by the height square (cm). Values between 18.5 to 24.9 is normal, while low weight if it lower than, 18.5 and values of 25 and above are considered as obese [3]. Obesity is the major public health problem with about 1.9 billion adults (18 years and older) worldwide are overweight and about 600 million of them are clinically obese [4]. Annually, 30 million people die

worldwide due to obesity and overweight [3]. Besides weight loss diet, exercise, and behavioral changes, using anti-obesity drugs have been reputed as a weight loss strategy in overweight and obese individuals. For the treatment of obesity, synthetic pharmaceutical drugs are used imposing high price and many complications. For this reason, patients and researchers are looking for alternative treatment methods such as the use of medicinal plants and their products for the treatment of obesity [5]. So the best option for the management of obesity is a lifestyle modification together with using natural alternatives that showed the minimal side effects. Natural Products are rich of bioactive compounds that have been used as traditional medicine. Some active natural products were tested by clinical trials and they showed a powerful impact in the treatment of obesity [6]. The main objective of this review is to focus on the recent advances in the natural products as anti-obesity potential. A major focus is to highlight the mechanisms of action of natural products as anti-obesity agents, preclinical and clinical trials were also discussed.

2. OBESITY

2.1. Definition

As it is a significant contributor to the global burden of chronic diseases such as; different types of cancer, type 2 diabetes mellitus and cardiovascular disease, obesity is currently one of the major public health issues. Obesity is a medical disorder, it is found as a result of imbalance between energy consumption and energy spending that leads to accumulation of excess body fat [1].

2.2. Classification

There are various methods for measuring the obesity, but the most widely-used method is Body Mass Index (BMI). Body mass index can be determined by dividing the weight (kg.) by the square of the height (cm). BMI is not a percentage of body fat. BMI is only part of a diagnosis of obesity [3].

2.2.1. Overweight

Having a BMI in the overweight range (25.0-29.9) is a health concern. Excess weight is hard on your body. It can lead to other health problems including obesity. People who have a BMI in the overweight range and have other health problems (such as type 2 diabetes or heart disease) need to see their healthcare provider for treatment options [7].

2.2.2. Obesity

Obesity is a disease where a person's weight is in an unhealthy range (BMI of 30.0-39.9). It is a disease that can lead to other health problems [7].

2.2.3. Severe Obesity

The person with BMI greater than 40 is considered as severe obesity case. Severe obesity has the greatest risk of other health problems. People with severe obesity need to see their healthcare provider for treatment options [7]. Increased weight circumference can also be a marker for increased risk even in persons of normal weight.

2.3. Causes

The weight of an individual is determined by the balance between intake of calories and energy consumption. The person gains weight if he eats more calories than he burns. A person will lose weight if he eats less calories than he metabolizes. Hence, physical inactivity and overeating are the most common causes of obesity [8, 9].

2.3.1. A diet high in simple carbohydrates

Blood glucose levels are elevated by carbohydrates, that activate pancreas to release insulin, and insulin stimulates the development of fat tissue and may induce weight gain. Some researchers suggest that simple carbohydrates lead to weight gain because they are absorbed into the bloodstream more easily than complex ones resulting in more insulin being released [1].

2.3.2. Genetics

When one or both parents are obese, a person is more likely to develop obesity. Hormones involved in fat control are also affected by genetics. For instance, leptin deficiency is one genetic cause of obesity. When body fat reserves are too high, leptin controls weight by signaling the brain to eat less. If, for some cause, the body cannot produce enough leptin or leptin cannot signal the brain to eat less, this control is lost,

and obesity occurs. The role of leptin replacement as a treatment for obesity is under exploration [8].

2.3.3. Effect of drugs

Medications associated with weight gain include certain antidepressants, anticonvulsants (medications used in controlling seizures such as carbamazepine and valproate), some diabetes medications (medications used in lowering blood sugar such as insulin, sulfonylureas, and thiazolidinediones), certain hormones such as oral contraceptives, and most corticosteroids such as prednisone. Some high blood pressure medications and antihistamines cause weight gain. The reason for the weight gain with the medications differs for each medication [8].

2.3.4. Physical inactivity

Active people burn more calories than sedentary people. There is a strong correlation between physical inactivity and weight gain in both sexes [10].

2.3.5. Overeating

Overeating leads to weight gain, especially if the diet is high in fat. Foods high in fat or sugar (for example, fast food, fried food, and sweets) have high energy density (foods that have a lot of calories in a small amount of food). Epidemiologic studies have shown that diets high in fat contribute to weight gain [11].

2.3.6. Frequency of eating

The relationship between frequency of eating (how often you eat) and weight is somewhat controversial. There are many reports of overweight people eating less often than people with normal weight. Scientists have observed that people who eat small meals four or five times daily, have lower cholesterol levels and lower and/or more stable blood sugar levels than people who eat two or three large meals daily. One possible explanation is that small frequent meals produce stable insulin levels, whereas large meals cause large spikes of insulin after meals [12].

2.3.7. Psychological factors

For some people, emotions influence eating habits. Many people eat excessively in response to emotions such as boredom, sadness, stress, or anger. While most overweight people have no more psychological disturbances than normal weight people, about 30% of the people who seek treatment for serious weight problems have difficulties with binge eating [12].

2.3.8. Diseases

Some diseases such as hypothyroidism, insulin resistance, polycystic ovary syndrome, and Cushing's syndrome are also contributors to obesity. Some diseases, such as Prader-Willi syndrome, can lead to obesity [9].

2.4. Health problems

People who have obesity, compared to those with a normal or healthy weight, are at increased risk for many serious diseases and health conditions, including: some types of cancer, cardiovascular disease, low quality of life, gallbladder disease, osteoarthritis, coronary heart disease, type 2 diabetes and dyslipidemia [2].

2.5. Treatment

2.5.1. Lifestyle Modification

The change in lifestyle includes introduction of behavioral and dietary changes that can be sustained indefinitely to promote health [13].

2.2.1. Dietary interventions

Dietary interventions for obesity are designed to create a negative energy balance (i.e., calories ingested < calories expended) by reducing daily energy intake below energy requirements. Uniformly, however, greater energy deficits result in greater weight losses [14].

2.2.2. Physical activity

The physical activity causes improving cardiovascular fitness, sparing fat-free mass during weight loss and increasing in calorie expenditure. Physical activity, however, produces minimal weight loss in the absence of caloric restriction. The greatest benefit of physical activity is in facilitating the maintenance of weight loss. Case studies have shown that people who exercise regularly are more successful in maintaining weight losses than are those who do not exercise [15].

2.2.3. Medications

As BMI or disease risk increase, more intensive options are available for the treatment of obesity. Pharmacotherapy is recommended for individuals with a BMI ≥ 30 kg/m². Two medications—sibutramine (Meridia) and orlistat (Xenical)—are approved by the Food and Drug Administration for the induction and maintenance of weight loss[16]. There are several barriers, however, to the long-term use of weight loss medications, including findings that most patients must pay out-of-pocket for anti-obesity agents[17].

2.2.4. Surgical Interventions

Bariatric surgery is appropriate only for those individuals with a BMI ≥ 40 kg/m² or BMI ≥ 35 kg/m² in the presence of comorbidities [18]. The two most common surgical procedures for obesity are vertical banded gastroplasty (VBG) and gastric bypass (GB). Both entail isolating a small (15- to 30-ml) pouch of stomach with a line of staples, thereby drastically limiting food intake. In VBG, the pouch empties into the remaining stomach, where the digestive process continues as normal. GB, however, not only restricts food intake, but also reduces absorption by bypassing the remaining stomach and 45–150 cm of small intestine. Bariatric surgery produces significant improvements in hypertension, asthma, sleep apnea, and diabetes. Improvements in mood have also been reported, but they appear to wane with time [19].

2.2.5. A new approach for the treatment

Actually, medications for the treatment of obesity are of two types; orlistat, which inhibits the absorption of fat via pancreatic lipase inhibition, and sibutramine which is an appetite suppressant. Both medications induce complications such as; constipation, insomnia, headache dry mouth and increased blood pressure. In 1997, the US FDA approved sibutramine for the treatment of obesity. But in 2010 due to

increased cardiovascular events and strokes, the drug was withdrawn from the market. Some medications can be abused such as diethylpropion and phentermine and hence are approved for short term use. So the conventional therapy of obesity mainly involves synthetic moieties and surgical procedures, which has many harmful side effects and chances of recurrence with severity. At the present, using anti-obesity drugs from natural products is in need because of the high cost and complications of synthetic drugs [4, 8].

2.2.6. Natural Products against obesity

This review focus on natural phyto extracts with their mechanism of action and their preclinical experimental model for further scientific research. Table 1 showed some important developments in the field of natural drug developments. The various phytoconstituents from these plants have shown more than one type of anti-obesity mechanisms including; increasing expression of PPAR- α and PPAR- γ , inhibition of ghrelin, reducing accumulation of white adipose tissue, regulating gene expression, inducing anorexia, pancreatic lipase inhibition and regulating plasma lipid profile. Furthermore, the major mechanism is reducing the lipid levels of plasma followed by suppression the activity of pancreatic lipase enzyme. While, no detailed researches highlight the molecular mechanism for anti-obesity activity. So, researchers have been motivated by the increasing threat of obesity to global health to put more effort into discovering an effective mechanism of action at molecular level.

Table 1: Medicinal plant for anti obesity activity

No.	Botanical name	Family	Plant part	Mode of action	Chemical constituents	Reference
1	<i>Platycodon grandiflorum</i>	Campanulaceae	Root	Increase lipid metabolism	Platycodins	[20]
2	<i>Garcinia cambogia</i>	Hypericaceae	Fruit	-Increase Hepatic acyl-CoA oxidase activity and lower the lipid levels -The release and availability of 5-hydroxytryptamine which is responsible for controlling apatite	Curcumin, hydroxycitric acid	[21,22]
3	<i>Prunus salicina</i>	Rosaceae	Plums	Suppress adipocyte differentiation ,reduce lipid accumulation ,modulation and regulations of molecular expressions like adenosine monophosphate-activated protein kinase.etc.	Polyphenols, flavonoids	[23]
4	<i>Glycine hispida</i>	Fabaceae	Whole soyben	Anti-oxidant and pancreatic lipase inhibition, controls serum lipid profile	Flavonoids and phenolic compounds	[24]
5	<i>Limonia acidissima</i>	Rutaceae	Bark	Anti-adipogenic effect and pancreatic lipase inhibition ,inhibition of PPAR and C/EBP , major adipogenic transcription factors, in 3T3L-1 preadipocytes	Flavonoids -oroxilin A, chrysin and baicalein	[25]
6	<i>Salix matsudana</i> (Chinese willow)	salicaceae	Leaves	Reduce plasma triglycerol levels and hepatic total cholesterol content ,also enhance nor-epinephrine induced lipolysis in fat cells	Apigenin-7-O-D-glucoside	[26]
7	<i>Camellia sinensis</i>	Theaceae	Leaves	Inhibiting the pancreatic lipase activity.	Flavonoids (theaflavin and thearubigins) Epigallocatechin 3-O-gallate (EGCG)	[27]
8	<i>Carallumafimbriata</i> Wall	Asclepiadaceae	Aerial parts	Reduce body weight gain by increasing water intake and decreasing hypothalamic levels of NPY and ORX peptides	Pregnaneglycosides,tannins and flavonoids	[28]
9	<i>Acanthopanax enticosus</i>	Araliaceae	Whole plant	Reduce serum LDL-cholesterol and liver Triglycerides	Carnitine	[29]
			Fruits	-Pancreatic lipase inhibition	Triterpenoid saponins	[30]
10	<i>Acanthopanax essiliflorus</i>	Araliaceae	Leaves	Pancreatic lipase inhibition	Saponins - lupane-type triterpene triglycosides	[31]
11	<i>Paulliniacupana</i>	Sapindaceae		Prevents triglycerol accumulation , up-regulation of the anti-adipogenic genes and down-regulation of pro-adipogenic genes	Phenolic compounds, flavonoids, Caffeine	[32]
12	<i>Salvia officinalis</i>	Lamiaceae	Leaves	Reduce the elevated triglycerides levels, reduced the weight gain of body	Carnosic acid and carnosol	[33]
13	<i>Gardenia jasminoides</i>	Rubiaceae	Fruit	Inhibition of pancreatic lipase	Crocin and crocin	[34]
			Flower	Decreases the absorption of fat and cholesterol from the diet by inhibiting the pancreatic lipase activity		[35]
14	<i>Panax ginseng</i>	Araliaceae	Roots,	Regulates body weight by reducing food intake and regulating pancreatic lipase	Ginseng crude saponins	[36]
			Berries, whole plant	Controls the obesity by inhibiting energy gain , regulating hypothalamic neuropeptides and serum biochemical	(protopanaxadiol, protopanaxatriol)	[37]
15	<i>Crocus sativus</i>	Iridaceae	Flower	Decreases the absorption of fat and cholesterol from the diet by inhibiting the pancreatic lipase activity	Crocin	[35]
16	<i>Glycyrrhizauralensis</i>	Fabaceae	Root	Reduce the production of oleic acid by inhibiting pancreatic lipase	Licochalcone A	[38]

17	<i>Cassia siamea</i>	Magnoliaceae	Bark	Anti-adipogenic effect and pancreatic lipase inhibition	Flavonoids -oroxylin A, chrysin and baicalein	[25]
18	<i>Nelumbonucifera gaertn</i>	Nymphaeaceae	Leaves	Accelerates lipid metabolism ,inhibition of alpha amylase and lipase, lower the serum total cholesterol, triglycerides, low density lipoproteins levels	Phenolic compounds	[39-41]
19	<i>Aesculus turbinata</i>	Sapindaceae	Seeds	Inhibition of pancreatic lipase	Saponins	[42]
20	<i>Cudratriaricuspidata</i>	Moraceae	Whole soyben	Anti-oxidant and pancreatic lipase inhibition	Polyphenolic compounds	[24]
21	<i>Citrus depressa</i>	Rutaceae	Fruits	Reduce white adipose tissue , reduced the plasma triglyceride , decreasing leptin levels	Flavonoids	[43]
22	<i>Carissa carandas</i>	Apocynaceae	Bark	Anti-adipogenic effect and pancreatic lipase inhibition	Flavonoids chrysin and baicalein	[25]
23	<i>Coffeaarabica</i> (Green Coffee bean)	Rubiaceae	Beans or seeds	Increase Energy expenditure	Polyphenols,chlorogenic acids	[44,45]
24	<i>Citrus unshiu</i>	Rutaceae	Dried peels	Significant reduction of serum triacylglycerol, total cholesterol through pancreatic lipase inhibition	Flavonoids and phenolic compounds	[46]
25	<i>Lonicera caerulea</i>	Caprifoliaceae	Whole soyben	Anti-oxidant and pancreatic lipase inhibition, controls serum lipid profile	Flavonoids and phenolic compounds	[24]
26	<i>Swertiachirayita</i>	Gentianaceae	Bark	Anti-adipogenic effect and pancreatic lipase inhibition	Flavonoids -oroxylin A, and chrysin	[25]
27	<i>Diospyros kaki</i>	Ebenaceae	Unripe fruit	Significant reduction of serum triacylglycerol, total cholesterol levels, and visceral fat through pancreatic lipase inhibition	Flavonoids and phenolic compounds	[46]
28	<i>Capsicum annum</i>	Solanaceae	Flowers	Anti-oxidant and pancreatic lipase inhibition	Flavonoids and phenolic compounds	[47]
29	<i>Oroxylum indicum</i>	Bignoniaceae	Bark	Anti-adipogenic effect and pancreatic lipase inhibition	Flavonoids	[25]
30	<i>Acacia mearnsii</i>	Mimosaceae	Bark	Suppression of body weight , maintain plasma glucose & insulin	Polyphenols – catechins	[48]
31	<i>Capparis decidua</i>	Capparaceae	Bark	Anti-adipogenic effect and pancreatic lipase inhibition	Flavonoids	[25]
32	<i>Cuscuta pedicellata</i>	Convolvulaceae		The reduction of insulin resistance and glucose tolerance, improving the cellular energy homeostasis and possession of antioxidant activity	Naringenin , kaempferol ,aromadendrin , quercetin	[1, 49,50]
33	<i>Zingiber officinale</i> (Ginger)	Zingiberaceae	rhizomes	Increasing thermogenesis and energy expenditure, increasing the lipolysis, inhibition of the intestinal absorption of dietary fat, and controlling the appetite	volatile oils including zingiberene,gingerol, shogaol, and zingerone.	[51-55]
34	<i>Cinnamomum zeylanicum</i>	Lauraceae	Bark	-Significantly reduced fat mass at the dosages of 2 g/d, when administered for 12 weeks. Inhibition of adipocyte by polyphenolic compounds; also they inhibited lipolysis, lipogenesis and intestinal lipid absorption that they tend to lowering weight.	Polyphenolic compounds cinnamaldehyde, cinnamate, cinnamic acid and eugenol	[51, 56-60]

3. CONCLUSION

This review points to the role of natural product in the management of obesity. It revealed that natural products include diversity of phytoconstituents that play an important role in the treatment of obesity. Furthermore, more

researches are required to confirm the effect of natural product as anti-obesity agents and to enter the drug discovery field.

4. REFERENCES

1. Marrelli M, Statti G, Conforti F. A Review of Biologically Active Natural Products from

- Mediterranean Wild Edible Plants: Benefits in the Treatment of Obesity and Its Related Disorders. *Molecules* 2020; 25: 649-69.
2. Payab M, Ranjbar S H, Aletaha A, Ghasemi N, Qorbani M, Atlasi R, Abdollahi M, Larijani B. Efficacy, safety, and mechanisms of herbal medicines used in the treatment of obesity. *Medicine* 2018; 17: 6-12.
 3. Bahmani M, Eftekhari Z, Saki K, Moghadam E F, Jelodari M, Kopaei M R. Obesity Phytotherapy: Review of Native Herbs Used in Traditional Medicine for Obesity. *J Evid Based Integr Med* 2015; 21: 228-34.
 4. Patra S, Nithya S, Srinithya B, Meenakshi S M. Review of Medicinal Plants for Anti-Obesity Activity. *Transl Biomed* 2015; 11: 320-32.
 5. Payab M, Ranjbar S H, Shahbal N, Qorbani M, Aletaha A, Aminjan H H, Soltani A, Khatami F, Nikfar S, Hassani S, Abdollahi M, Bagher L. Effect of the herbal medicines in obesity and metabolic syndrome: A systematic review and meta-analysis of clinical trials. *Phyther Res* 2019; 12: 1–20.
 6. Barrea L, Altieri B, Polese B, Conno B D, Muscogiuri G, Colao A. Nutritionist and obesity: brief overview on efficacy, safety, and drug interactions of the main weight-loss dietary supplements. *Int J Obes Suppl* 2019; 9: 32–49.
 7. Aronne L J. Classification of Obesity and Assessment of Obesity-Related Health Risks. *Obes Res* 2002; 10: 105-15.
 8. Karri S, Sharma S, Hatware K, Patil K. Natural anti-obesity agents and their therapeutic role in management of obesity: A future trend perspective. *Biomed Pharmacother* 2019; 110: 224–38.
 9. Wright S M, Aronne L J. Causes of obesity. *Abdominal* Published 2012; 37: 730–2.
 10. Kimm S Y, Glynn N W, Kriska A M. Decline in physical activity in black girls and white girls during adolescence. *The New England Journal of Medicine* 2002; 347: 709–15.
 11. Bora K. Obesity: Causes and Consequences. *Metabolic Bone Disease and Related Research* 2016; 30: 223-42.
 12. Pradeepa R, Anjana R M, Joshi S R, Bhansali A, Deepa M, Joshi P P. Prevalence of generalized and abdominal obesity in urban and rural India – the ICMR INDIAB Study (Phase 1) [ICMR-INDIAB-3]. *Ind J Med Res* 2015; 142: 139-50.
 13. Fabricatore A N, Wadden T A. Treatment of Obesity: An Overview. *Clin Diabetes* 2003; 21: 67-72.
 14. Ayyad C, and Andersen T. Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. *Obes Rev* 2000; 1: 113–9.
 15. Bensimhon D R, Kraus W E, Donahue M P. Obesity and physical activity: a review. *Am Heart J* 2006; 151: 598-603.
 16. Gray L J, Cooper N, Dunkley A, Warren F C, Ara R, Abrams K, Davies M J, Khunti K. A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity. *Obes Rev* 2012; 13: 483-98.
 17. Rodgers R J, Tschöp M H, and Wilding J P H. Anti-obesity drugs: past, present and future. *DMM* 2012; 5: 621-6.
 18. Albaugh V L, and Abumrad N N. Surgical treatment of obesity. *F1000 Research* 2018; 20 :617-30.
 19. Dixon J B, Straznicki N E, Lambert E A, Schlaich M P, Gavin W. Surgical approaches to the treatment of obesity. *Nat Rev Gastroenterol Hepatol* 2011; 8: 429–37.
 20. Han L K, Xu B J, Kimura Y, Zheng Y, Okuda H. *Platycodi radix* Affects Lipid Metabolism in Mice with High Fat Diet-Induced Obesity. *J Nutr* 2000; 130: 2760–4.
 21. Asai A, Miyazawa T. Dietary curcuminoids prevent high-fat diet-induced lipid accumulation in rat liver and epididymal adipose tissue. *J Nutr* 2001; 131: 2932–5.
 22. Ohia S E, Opere C A, Le Day A M, Bagchi M, Bagchi D, Stohs S J. Safety and mechanism of appetite suppression by a novel hydroxycitric acid extract (HCASX). *Mol Cell Biochem* 2002; 238: 89–103.
 23. Choe W K, Kang B T., Kim S O. Water-extracted plum (*Prunus salicina* L. Cv. Soldam) attenuates adipogenesis in murine 3T3-L1 adipocyte cells through the PI3K/Akt signaling pathway. *Exp Ther Med* 2018; 15: 1608–15.
 24. Suh D H, Jung E S, Park H M, Kim S H, Lee S, Jo Y H, Lee M K, Jung G, Do S G, Lee C H. Comparison of metabolites variation and antiobesity effects of fermented versus nonfermented mixtures of *Cudratriaricuspidata*, *Lonicera caerulea*, and soybean according to fermentation *in vitro* and *in vivo*. *PLoS* 2016; 11: 317-36.
 25. Mangal P, Khare P, Jagtap S, Bishnoi M, Kondepudi K K, Bhutani K K. Screening of six Ayurvedic medicinal plants for anti-obesity potential: an investigation on bioactive constituents from *Oroxylum indicum* (L.) Kurz bark. *J Ethnopharmacol* 2017; 197: 138-46.
 26. Han L, Sumiyoshi M, Zheng Y, Okuda H, Kimura Y. Anti-obesity action of *Salix matsudana* leaves (Part 2). Isolation of anti-obesity effectors from polyphenol fractions of *Salix matsudana*. *Phyther Res* 2003; 17: 1195–8.
 27. Nakai M, Fukui Y, Asami S, Toyoda Y, Iwashita T, Shibata H, Mitsunaga T, Hashimoto F, Kiso Y. Inhibitory effects of oolong tea polyphenols on pancreatic lipase *in vitro*. *J Agric Food Chem* 2005; 53: 4593–8.
 28. Vitalone A, Di Sotto A, Mammola C L, Heyn R, Miglietta S, Mariani P, Sciubba F, Passarelli F, Nativio P, Mazzanti G. Phytochemical analysis and effects on ingestive behaviour of a *Carallum afimbriata* extract. *Food Chem Toxicol* 2017; 108: 63–73.

29. Cha Y S, Rhee S J, Heo Y R. *Acanthopanaxsenticosus* extract prepared from cultured cells decreases adiposity and obesity indices in C57BL/6J mice fed a high fat diet. *J Med Food* 2004; 7: 422–9.
30. Li F, Li W, Fu H, Zhang Q, Koike K. Pancreatic lipase-inhibiting triterpenoid saponins from fruits of *Acanthopanaxsenticosus*. *Chem Pharm Bull* 2007;55: 1087–9.
31. Yoshizumi K, Hirano K, Ando H, Hirai Y, Ida Y, Tsuji T, Tanaka T, Satouchi K, Terao J. Lupane-type saponins from leaves of *Acanthopanaxsessiliflorus* and their inhibitory activity on pancreatic lipase. *J Agric Food Chem* 2006; 54: 335–41.
32. Lima N S, Numata E P, Mesquita L M S, Dias P H, Vilegas W, Gambero A, Ribeiro M L. Modulatory effects of guarana (*Paullinia cupana*) on Adipogenesis. *Nutrients* 2017; 9: 635–53.
33. Ninomiya K, Matsuda H, Shimoda H, Nishida N, Kasajima N, Yoshino T, et al. Carnosic acid, a new class of lipid absorption inhibitor from sage. *Bioorg Med Chem Lett* 2004; 14: 1943–6.
34. Lee I A, Lee J H, Baek N I, Kim D H. Antihyperlipidemic effect of crocin isolated from the fruits of *Gardenia jasminoides* and its metabolite crocetin. *Biol Pharm Bull* 2015; 28: 2106–10.
35. Sheng L, Qian Z, Zheng S, Xi L. Mechanism of hypolipidemic effect of crocin in rats: crocin inhibits pancreatic lipase. *Eur J Pharmacol* 2006; 543: 116–22.
36. Kim J H, Hahm D H, Yang D C, Kim J H, Lee H J, Shim I. Effect of crude saponin of Korean red ginseng on high-fat diet-induced obesity in the rat. *J Pharmacol Sci* 2005; 97: 124–31.
37. Kim J H, Kang S A, Han S, Shim I. Comparison of the antiobesity effects of the Protopanaxadiol- and protopanaxatriol-type saponins of red ginseng. *Phytother Res* 2009; 23: 78–85.
38. Won S R, Kim S K, Kim Y M, Lee P H, Ryu J H, Kim J W, et al. Licochalcone A: a lipase inhibitor from the roots of *Glycyrrhiza uralensis*. *Food Res Int* 2007; 40: 1046–50.
39. Ono Y, Hattori E, Fukaya Y, Imai S, Ohizumi Y. Anti-obesity effect of *Nelumbonucifera* leaves extract in mice and rats. *J Ethnopharmacol* 2006; 106: 238–44.
40. Du H, You J S, Zhao X, Park J Y, Kim S H, Chang K J. Antiobesity and hypolipidemic effects of lotus leaf hot water extract with taurine supplementation in rats fed a high fat diet. *J Biomed Sci* 2010; 17: 42–54.
41. Liu S, Li D, Huang B, Chen Y, Lu X, Wang Y. Inhibition of pancreatic lipase, α -glucosidase, α -amylase, and hypolipidemic effects of the total flavonoids from *Nelumbonucifera* leaves. *J Ethnopharmacol* 2013; 149: 263–9.
42. Hu J N, Zhu X M, Han L K, Saito M, Sun Y S, Yoshikawa M, Kimura Y, Zheng Y N. Anti-obesity effects of escins extracted from the seeds of *Aesculus turbinata* Blume (Hippocastanaceae). *Chem Pharm Bull* 2008; 56: 12–6.
43. Lee Y S, Cha B Y, Saito K, Choi S S, Wang X X, Choi B K, Yonezawa T, Teruya T, Nagai K, Woo J T. Effects of a *Citrus depressa* Hayata (shikuwasa) extract on obesity in high-fat diet-induced obese mice. *Phytomedicine* 2011; 18: 648–54.
44. Murase T, Misawa K, Minegishi Y, Aoki M, Ominami H, Suzuki Y, Shibuya Y, Hase T. Coffee polyphenols suppress diet-induced body fat accumulation by downregulating SREBP-1c and related molecules in C57BL/6J mice. *Am J Physiol Endocrinol Metab* 2010; 300: 122–33.
45. Shimoda H, Seki E, Aitani M. Inhibitory effect of green coffee bean extract on fat accumulation and body weight gain in mice. *BMC Complement Altern Med* 2006; 6: 1–9.
46. Kim G N, Shin M R, Shin S H, Lee A R, Lee J Y, Seo B I, Kim M Y, Kim T H, Noh J S, Rhee M H. Study of antiobesity effect through inhibition of pancreatic lipase activity of *Diospyros kaki* fruit and *Citrus unshiu* peel. *Biomed Res Int* 2016; 300: 122–33.
47. Tan S, Gao B, Tao Y, Guo J, Su Z. Antiobese effects of capsaicin–chitosan microsphere (CCMS) in obese rats induced by high fat diet. *J Agric Food Chem* 2015; 62: 1866–74.
48. Ogawa S, Yazaki Y. Tannins from *Acacia mearnsii* De Wild. Bark: Tannin Determination and Biological Activities. *Molecules* 2018; 23: 837–45.
49. Zekry S H, Abo-elmatty D M, Zayed R A, Radwan M M, ElSohly M A, Hassanean H A, Ahmed S A. Effect of metabolites isolated from *Cuscuta pedicellata* on high fat diet-fed rats. *Med Chem Res* 2015; 24: 1964–73.
50. Mehanna E T, El-sayed N M, Ibrahim A K, Ahmed S A, Abo-Elmatty D M. Isolated compounds from *Cuscuta pedicellata* ameliorate oxidative stress and upregulate expression of some energy regulatory genes in high fat diet induced obesity in rats. *Biomed Pharmacother* 2018; 108: 1253–8.
51. Abdel Raouf G F, Mohamed K Y, Mohammed H M. Phytochemical Evaluation, Anti-obesity and Antihyperlipidemic Effects of Combined Administration of Green Coffee, Cinnamon and Ginger. *Sciencepc* 2017; 5: 80–4.
52. Attari V E, Mahdavi A M, Javadi Vala Z, Mahluji S, Vahed S Z, Ostadrahimi A. A systematic review of the anti-obesity and weight lowering effect of ginger (*Zingiber officinale Roscoe*) and its mechanisms of action. *Phytother Res* 2017; 32: 577–85.
53. Akhani S P, Vishwakarma S L, Goyal R K. Anti-diabetic activity of *Zingiber officinale* in streptozotocin-induced type I diabetic rats. *J Pharm Pharmacol* 2004; 56: 101–5.
54. El Rokhel S M, Yassin N A, El-Shenawy S M, Ibrahim B M. Antihypercholesterolaemic effect of ginger

- rhizome (*Zingiber officinale*) in rats. *Inflammopharmacology* 2010; 18: 309-15.
55. Abdel-Azeem A S, Hegazy A M., Ibrahim K S, Farrag A R, El-Sayed E M Hepatoprotective, antioxidant, and ameliorative effects of ginger (*Zingiber officinale* Roscoe) and vitamin E in acetaminophen treated rats. *J Diet Suppl* 2013;10: 195-209.
56. Mousavi S M, Rahmani J, Varkaneh H K, Sheikhi A, Larijani B, Esmailzadeh A. Cinnamon supplementation positively affects obesity: A systematic review and dose-response meta-analysis of randomized controlled trials. *Clin Nutr* 2020; 39: 123-33.
57. Azab K S h, Mostafa A H, Ali E M, Abdel-Aziz M A. Cinnamon extract ameliorates ionizing gradiation-induced cellular injury in rats. *Ecotoxicol Environ Saf*, 2011;74: 2324-9.
58. Vafa M, Mohammadi F, Shidfar F, Sormaghi M S, Heidari I, Golestan B, *et al.* Effects of cinnamon consumption on glycemic status, lipid profile and body composition in type 2 diabetic patients. *Int J Prev Med* 2012; 3: 531-6.
59. Shatwan I A, Ahmed L A, Badkook M M. Effect of barley flour, crude cinnamon, and their combination on glycemia, dyslipidemia, and adipose tissue hormones in type 2 diabetic rats. *J Med Food* 2013;16: 656-62.
60. Lee S. C., Xu W. X., Lin L. Y., Yang J. J., Liu C. T. Chemical composition and hypoglycemic and pancreas-protective effect of leaf essential oil from indigenous cinnamon (*Cinnamomum osmophloeum* Kanehira). *J Agric Food Chem* 2013;61:4905.

Conflict of Interest: None

Source of Funding: Nil